{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:12:52Z","timestamp":1787613172635,"version":"build-2736575974"},"reference-count":218,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.resinv.2024.11.015","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:01:09Z","timestamp":1733367669000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular mechanisms and clinical impact of biologic therapies in severe asthma"],"prefix":"10.1016","volume":"63","author":[{"given":"Hiroki","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kuwahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0461-5072","authenticated-orcid":false,"given":"Koichiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.11.015_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1056\/NEJMra1608969","article-title":"Severe and difficult-to-treat asthma in adults","volume":"377","author":"Israel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1155\/2010\/361071","article-title":"Direct health care costs associated with asthma in British Columbia","volume":"17","author":"Sadatsafavi","year":"2010","journal-title":"Can Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.jaci.2016.04.004","article-title":"The discovery of IgE","volume":"137","author":"Johansson","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1183\/13993003.01824-2014","article-title":"Asthma phenotypes and IgE responses","volume":"47","author":"Froidure","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/antib8010019","article-title":"IgE antibodies: from structure to function and clinical translation","volume":"8","author":"Sutton","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.resinv.2024.11.015_bib7","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri3632","article-title":"The production and regulation of IgE by the immune system","volume":"14","author":"Wu","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib8","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1146\/annurev.immunol.17.1.931","article-title":"The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology","volume":"17","author":"Kinet","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib9","doi-asserted-by":"crossref","first-page":"B24","DOI":"10.1038\/35037021","article-title":"Signalling through the high-affinity IgE receptor Fc epsilonRI","volume":"402","author":"Turner","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2024.11.015_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.resinv.2024.11.015_bib11","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaci.2007.01.017","article-title":"Proximal signaling events in Fc epsilon RI-mediated mast cell activation","volume":"119","author":"Kambayashi","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1067\/mai.2001.116124","article-title":"IgE-mediated mast cell degranulation and recovery monitored by time-lapse photography","volume":"108","author":"Xiang","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1164\/rccm.202110-2322ED","article-title":"Mechanisms of mast cell activation in severe asthma: beyond IgE","volume":"205","author":"Bradding","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/cea.12675","article-title":"Mast cells in asthma--state of the art","volume":"46","author":"Bradding","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1067\/mai.2001.115625","article-title":"Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitization","volume":"107","author":"Tumas","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib16","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.4049\/jimmunol.169.4.2061","article-title":"IgE-dependent mast cell activation potentiates airway responses in murine asthma models","volume":"169","author":"Mayr","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1073\/pnas.94.4.1344","article-title":"Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma","volume":"94","author":"Mehlhop","year":"1997","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.resinv.2024.11.015_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-020-00442-0","article-title":"Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma","volume":"16","author":"Henriksen","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1067\/mai.2003.54","article-title":"Omalizumab improves asthma-related quality of life in patients with severe allergic asthma","volume":"111","author":"Finn","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\"Real-life\" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231221771","article-title":"Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.resinv.2024.11.015_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jaip.2020.10.027","article-title":"Possible protective effect of omalizumab on lung function decline in patients experiencing asthma exacerbations","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib28","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe asthma network Italy definition of clinical remission in severe asthma: a delphi consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib29","first-page":"1","article-title":"Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab","author":"Cilli","year":"2024","journal-title":"J Asthma"},{"key":"10.1016\/j.resinv.2024.11.015_bib30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jaip.2024.01.044","article-title":"Targeting asthma remission as the next therapeutic step toward improving disease control","volume":"12","author":"Busse","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","article-title":"Immunological and clinical changes in allergic asthmatics following treatment with omalizumab","volume":"131","author":"Noga","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000090387","article-title":"Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma","volume":"139","author":"Prieto","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and hematological effects of IL-5(Ralpha)-targeted therapy: an overview","volume":"73","author":"Hassani","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib37","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating severe asthma: targeting the IL-5 pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib38","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.4049\/jimmunol.124.5.2414","article-title":"Antigen-induced T cell-replacing factor (TRF). I. Functional characterization of a TRF-producing helper T cell subset and genetic studies on TRF production","volume":"124","author":"Takatsu","year":"1980","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.alit.2023.12.002","article-title":"Thymic stromal lymphopoietin contributes to ozone-induced exacerbations of eosinophilic airway inflammation via granulocyte colony-stimulating factor in mice","volume":"73","author":"Kurihara","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90721","article-title":"Prolonged activation of IL-5-producing ILC2 causes pulmonary arterial hypertrophy","volume":"2","author":"Ikutani","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.resinv.2024.11.015_bib42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2183\/pjab.87.463","article-title":"Interleukin-5 and IL-5 receptor in health and diseases","volume":"87","author":"Takatsu","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.resinv.2024.11.015_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0065-2776(08)60673-2","article-title":"Interleukin-5 and its receptor system: implications in the immune system and inflammation","volume":"57","author":"Takatsu","year":"1994","journal-title":"Adv Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib44","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/j.1460-2075.1992.tb05437.x","article-title":"Critical cytoplasmic domains of the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation","volume":"11","author":"Sakamaki","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.resinv.2024.11.015_bib45","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib46","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.resinv.2024.11.015_bib47","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1084\/jem.172.5.1425","article-title":"Eosinophilia in transgenic mice expressing interleukin 5","volume":"172","author":"Dent","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib48","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1084\/jem.185.12.2143","article-title":"Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma","volume":"185","author":"Lee","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0091-6749(95)70039-0","article-title":"Eosinophil infiltration precedes development of airway hyperreactivity and mucosal exudation after intranasal administration of interleukin-5 to mice","volume":"96","author":"Van Oosterhout","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib50","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0091-6749(93)90085-T","article-title":"Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge","volume":"92","author":"Ohnishi","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib51","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1046\/j.1365-2222.2000.00828.x","article-title":"Allergen-induced airway inflammation and bronchial responsiveness in interleukin-5 receptor alpha chain-deficient mice","volume":"30","author":"Tanaka","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib52","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1111\/all.15914","article-title":"Novel mechanisms by which benralizumab suppresses IgE expression in human B cells in humanized mice","volume":"78","author":"Nunomura","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib53","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib54","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.11.015_bib55","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2024.11.015_bib56","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib57","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib59","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.resinv.2024.11.015_bib60","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2023.05.025","article-title":"Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naive patients with severe eosinophilic asthma: experience of 3 Years' therapy","volume":"11","author":"Fyles","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib62","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.alit.2018.04.003","article-title":"Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma","volume":"67S","author":"Soma","year":"2018","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib64","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.09.008","article-title":"Clinical associations of mucus plugging in moderate to severe asthma","volume":"11","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib67","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.chest.2022.03.003","article-title":"Asthma control, airway mucus, and (129)Xe MRI ventilation after a single benralizumab dose","volume":"162","author":"McIntosh","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.11.015_bib68","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.chest.2023.02.009","article-title":"CT mucus score and (129)Xe MRI ventilation defects after 2.5 Years' anti-IL-5ralpha in eosinophilic asthma","volume":"164","author":"McIntosh","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.11.015_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13103013","article-title":"Unlocking the long-term effectiveness of benralizumab in severe eosinophilic asthma: a three-year real-life study","volume":"13","author":"Pini","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2022.10.028","article-title":"Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma","volume":"151","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib72","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"9","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib73","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1084\/jem.155.3.914","article-title":"Identification of a T cell-derived b cell growth factor distinct from interleukin 2","volume":"155","author":"Howard","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib74","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2015.01.038","article-title":"History of interleukin-4","volume":"75","author":"Paul","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.resinv.2024.11.015_bib75","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.4049\/jimmunol.136.12.4538","article-title":"B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells","volume":"136","author":"Coffman","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib76","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins","volume":"136","author":"Mosmann","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib77","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1126\/science.270.5243.1845","article-title":"Role of NK1.1+ T cells in a TH2 response and in immunoglobulin E production","volume":"270","author":"Yoshimoto","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.resinv.2024.11.015_bib78","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1073\/pnas.88.7.2835","article-title":"Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils","volume":"88","author":"Seder","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.resinv.2024.11.015_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/339064a0","article-title":"Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores","volume":"339","author":"Plaut","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2024.11.015_bib80","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.4049\/jimmunol.155.6.3234","article-title":"Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils","volume":"155","author":"Nonaka","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib81","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature08636","article-title":"Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells","volume":"463","author":"Moro","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2024.11.015_bib82","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028449","article-title":"The common cytokine receptor gamma chain family of cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.resinv.2024.11.015_bib83","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","article-title":"The IL-4 receptor: signaling mechanisms and biologic functions","volume":"17","author":"Nelms","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib84","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/eji.1830270425","article-title":"A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4\/interleukin-13 receptor","volume":"27","author":"Gauchat","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib85","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1002\/(SICI)1521-4141(199812)28:12<4286::AID-IMMU4286>3.0.CO;2-H","article-title":"The distribution of IL-13 receptor alpha1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4","volume":"28","author":"Graber","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: a novel treatment for asthma","volume":"7","author":"Vatrella","year":"2014","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12703\/r\/10-71","article-title":"Recent advances in understanding the role of IL-4 signaling","volume":"10","author":"Keegan","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.resinv.2024.11.015_bib88","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2024.07.012","article-title":"Multiomics analysis identified IL-4-induced IL1RL1(high) eosinophils characterized by prominent cysteinyl leukotriene metabolism","volume":"154","author":"Sunata","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib89","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/362248a0","article-title":"Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses","volume":"362","author":"Minty","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2024.11.015_bib90","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1084\/jem.167.4.1350","article-title":"Heterogeneity of helper\/inducer T lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes","volume":"167","author":"Boom","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000237431","article-title":"Role of IL-13 in CD4 T cell-dependent IgE production in atopy","volume":"112","author":"Levy","year":"1997","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib92","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fphar.2019.01387","article-title":"The intriguing role of interleukin 13 in the pathophysiology of asthma","volume":"10","author":"Marone","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.resinv.2024.11.015_bib93","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaci.2012.06.034","article-title":"IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies","volume":"130","author":"Ingram","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib94","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/all.13424","article-title":"Role of IL-13Ralpha2 in modulating IL-13-induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa","volume":"73","author":"Liu","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1365-2249.1998.00471.x","article-title":"The role of IL-13 in IgE synthesis by allergic asthma patients","volume":"111","author":"Van der Pouw Kraan","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib96","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1067\/mai.2001.118600","article-title":"IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism","volume":"108","author":"Pope","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib97","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1023\/B:JOCI.0000029111.27168.c6","article-title":"Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells","volume":"24","author":"Ramirez-Icaza","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib98","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1172\/JCI5909","article-title":"Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production","volume":"103","author":"Zhu","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.resinv.2024.11.015_bib99","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1365-2222.2008.02969.x","article-title":"IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells","volume":"38","author":"Chibana","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1067\/mai.2001.112265","article-title":"IL-12\/IL-13 axis in allergic asthma","volume":"107","author":"Wills-Karp","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib101","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1084\/jem.189.10.1565","article-title":"Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses","volume":"189","author":"McKenzie","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2009.01.003","article-title":"Unique and overlapping gene expression patterns driven by IL-4 and IL-13 in the mouse lung","volume":"123","author":"Lewis","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib103","doi-asserted-by":"crossref","first-page":"7716","DOI":"10.4049\/jimmunol.174.12.7716","article-title":"IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13","volume":"174","author":"Fish","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1165\/rcmb.2012-0500OC","article-title":"An IL-4\/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice","volume":"49","author":"Kasaian","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2024.11.015_bib105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib106","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib107","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib108","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2024.03.031","article-title":"Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma","volume":"12","author":"Pavord","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.11.043","article-title":"Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma","volume":"11","author":"Pavord","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib110","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib111","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","article-title":"Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial","volume":"208","author":"Svenningsen","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1074","article-title":"Successful treatment with dupilumab for mucus plugs in severe asthma","volume":"11","author":"Anai","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.resinv.2024.11.015_bib113","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.alit.2020.08.006","article-title":"Efficacy of dupilumab and biomarkers for systemic corticosteroid naive allergic bronchopulmonary mycosis","volume":"70","author":"Tashiro","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib114","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.alit.2024.02.002","article-title":"Efficacy of dupilumab for airway hypersecretion and airway wall thickening in patients with moderate-to-severe asthma: a prospective, observational study","volume":"73","author":"Tajiri","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13010291","article-title":"Clinical remission in patients affected by severe eosinophilic asthma on dupilumab therapy: a long-term real-life study","volume":"13","author":"Quarato","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107720","article-title":"Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world cohort study","volume":"231","author":"Bult","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.alit.2022.11.006","article-title":"Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma","volume":"72","author":"Kurihara","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib118","first-page":"321","article-title":"A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells","volume":"22","author":"Friend","year":"1994","journal-title":"Exp Hematol"},{"key":"10.1016\/j.resinv.2024.11.015_bib119","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4049\/jimmunol.162.2.677","article-title":"Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism","volume":"162","author":"Levin","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib120","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib121","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/ni1048","article-title":"Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4+ T cell homeostatic expansion","volume":"5","author":"Watanabe","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib122","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4049\/jimmunol.1100355","article-title":"Thymic stromal lymphopoietin is produced by dendritic cells","volume":"187","author":"Kashyap","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib123","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejphar.2011.09.163","article-title":"Naringenin suppresses the production of thymic stromal lymphopoietin through the blockade of RIP2 and caspase-1 signal cascade in mast cells","volume":"671","author":"Moon","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.resinv.2024.11.015_bib124","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib125","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/13543784.2019.1672657","article-title":"Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma","volume":"28","author":"Marone","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.resinv.2024.11.015_bib126","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/B978-0-12-404717-4.00004-4","article-title":"The biology of thymic stromal lymphopoietin (TSLP)","volume":"66","author":"Ziegler","year":"2013","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.resinv.2024.11.015_bib127","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000567","article-title":"Distinct signal codes generate dendritic cell functional plasticity","volume":"3","author":"Arima","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.resinv.2024.11.015_bib128","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/ncomms3675","article-title":"Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation","volume":"4","author":"Kabata","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.resinv.2024.11.015_bib129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni956","article-title":"Thymic stromal-derived lymphopoietin distinguishes fetal from adult B cell development","volume":"4","author":"Vosshenrich","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib131","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41385-020-0266-x","article-title":"Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation","volume":"13","author":"Kabata","year":"2020","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib132","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.11.015_bib133","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib134","first-page":"A3046","article-title":"Single cell RNA sequencing reveals the crucial role of dendritic cell for ozone-induced pulmonary responses via thymic stromal lymphopoietin","volume":"209","author":"Tashiro","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2222.2008.03151.x","article-title":"Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions","volume":"39","author":"Tanaka","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.03.032","article-title":"TSLP drives acute T(H)2-cell differentiation in lungs","volume":"146","author":"Lai","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib137","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib138","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S2213-2600(21)00537-3","article-title":"Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib139","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300135","article-title":"Tezepelumab and mucus plugs in patients with moderate-to-severe asthma","volume":"2","author":"Nordenmark","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.resinv.2024.11.015_bib140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0952-7915(01)00306-5","article-title":"IL-1 and IL-18 receptors, and their extended family","volume":"14","author":"Sims","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib141","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.resinv.2024.11.015_bib142","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2008.00713.x","article-title":"Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites","volume":"226","author":"Saenz","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.resinv.2024.11.015_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.08.051","article-title":"IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity","volume":"143","author":"Ravanetti","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157571","article-title":"Interleukin-33 from monocytes recruited to the lung contributes to house dust mite-induced airway inflammation in a mouse model","volume":"11","author":"Tashiro","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2024.11.015_bib145","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.resinv.2024.11.015_bib146","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2332\/allergolint.10-RAI-0186","article-title":"IL-33 and IL-33 receptors in host defense and diseases","volume":"59","author":"Oboki","year":"2010","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib147","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2024.11.015_bib148","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12967-023-04782-4","article-title":"Role of IL-33-ST2 pathway in regulating inflammation: current evidence and future perspectives","volume":"21","author":"Zhou","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib149","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imcb.12200","article-title":"IL-33 regulates cytokine production and neutrophil recruitment via the p38 MAPK-activated kinases MK2\/3","volume":"97","author":"McCarthy","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.resinv.2024.11.015_bib150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.mucimm.2023.09.006","article-title":"The IL-17A-neutrophil axis promotes epithelial cell IL-33 production during nematode lung migration","volume":"16","author":"Ajendra","year":"2023","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib151","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/intimm\/dxn037","article-title":"Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system","volume":"20","author":"Kondo","year":"2008","journal-title":"Int Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib152","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1038\/s41598-017-03674-0","article-title":"Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, inflammation and remodeling in a mouse model of asthma","volume":"7","author":"Sjoberg","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2024.11.015_bib153","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jaci.2013.05.012","article-title":"IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction","volume":"132","author":"Barlow","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib154","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1073\/pnas.1003059107","article-title":"IL-33 is a crucial amplifier of innate rather than acquired immunity","volume":"107","author":"Oboki","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.resinv.2024.11.015_bib155","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.4049\/jimmunol.1900690","article-title":"Endogenous IL-33 and its autoamplification of IL-33\/ST2 pathway play an important role in asthma","volume":"204","author":"Magat","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib156","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1084\/jem.20170449","article-title":"IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow","volume":"215","author":"Stier","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib157","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/all.12590","article-title":"Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells","volume":"70","author":"Sjoberg","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib158","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1172\/JCI126402","article-title":"Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling","volume":"129","author":"Altman","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.resinv.2024.11.015_bib159","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib160","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib161","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1002\/j.1460-2075.1994.tb06715.x","article-title":"Molecular characterization of murine and human OX40\/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34","volume":"13","author":"Baum","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.resinv.2024.11.015_bib162","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1074\/jbc.272.8.5275","article-title":"Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells","volume":"272","author":"Al-Shamkhani","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2024.11.015_bib163","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/j.1460-2075.1990.tb08211.x","article-title":"Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor","volume":"9","author":"Mallett","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.resinv.2024.11.015_bib164","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/eji.1830250410","article-title":"Gene structure and chromosomal localization of the mouse homologue of rat OX40 protein","volume":"25","author":"Birkeland","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib165","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1074\/jbc.273.10.5808","article-title":"Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation","volume":"273","author":"Kawamata","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2024.11.015_bib166","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/MCB.18.1.558","article-title":"4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB","volume":"18","author":"Arch","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.resinv.2024.11.015_bib167","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.4049\/jimmunol.159.8.3838","article-title":"Expression and function of OX40 ligand on human dendritic cells","volume":"159","author":"Ohshima","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib168","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.resinv.2024.11.015_bib169","article-title":"Regulation of T Cell immunity by OX40 and OX40L","author":"Croft","year":"2013","journal-title":"Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013."},{"key":"10.1016\/j.resinv.2024.11.015_bib170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1084\/jem.193.3.387","article-title":"Development of allergic inflammation in a murine model of asthma is dependent on the costimulatory receptor OX40","volume":"193","author":"Jember","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib171","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.jaci.2020.10.037","article-title":"Combination blockade of OX40L and CD30L inhibits allergen-driven memory T(H)2 cell reactivity and lung inflammation","volume":"147","author":"Gracias","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib172","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/eji.200323455","article-title":"Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma","volume":"33","author":"Hoshino","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib173","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1378\/chest.09-1839","article-title":"Airway wall expression of OX40\/OX40L and interleukin-4 in asthma","volume":"137","author":"Siddiqui","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.11.015_bib174","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nri1371","article-title":"Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40","volume":"4","author":"Sugamura","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cea.12235","article-title":"OX40L blockade and allergen-induced airway responses in subjects with mild asthma","volume":"44","author":"Gauvreau","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib176","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.resinv.2024.11.015_bib177","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib178","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib179","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib180","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib181","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.resinv.2024.11.015_bib182","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib183","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1439","article-title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease","volume":"8","author":"Qian","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib184","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1084\/jem.191.7.1233","article-title":"Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction","volume":"191","author":"Schwandner","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib185","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/ni.2081","article-title":"Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)","volume":"12","author":"Sun","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib186","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4049\/jimmunol.1203315","article-title":"HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 mRNA stabilization","volume":"191","author":"Herjan","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1744666X.2023.2125380","article-title":"The emerging role of IL-23 in asthma and its clinical implications","volume":"19","author":"Wu","year":"2023","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.resinv.2024.11.015_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.694514","article-title":"Pharmacological rationale for targeting IL-17 in asthma","volume":"2","author":"Rahmawati","year":"2021","journal-title":"Front Allergy"},{"issue":"Suppl 1","key":"10.1016\/j.resinv.2024.11.015_bib189","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2332\/allergolint.13-OA-0632","article-title":"Dual role of interleukin-23 in epicutaneously-sensitized asthma in mice","volume":"63","author":"Masaki","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/cr.2009.128","article-title":"IL-23 signaling enhances Th2 polarization and regulates allergic airway inflammation","volume":"20","author":"Peng","year":"2010","journal-title":"Cell Res"},{"key":"10.1016\/j.resinv.2024.11.015_bib191","doi-asserted-by":"crossref","DOI":"10.1038\/srep18680","article-title":"Ozone-induced IL-17A and neutrophilic airway inflammation is orchestrated by the caspase-1-IL-1 cascade","volume":"6","author":"Che","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2024.11.015_bib192","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm.3423","article-title":"Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity","volume":"20","author":"Kim","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib193","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12865-014-0039-y","article-title":"beta2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells","volume":"15","author":"Kato","year":"2014","journal-title":"BMC Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib194","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s10753-017-0550-4","article-title":"Saturated fatty acid increases lung macrophages and augments house dust mite-induced airway inflammation in mice fed with high-fat diet","volume":"40","author":"Tashiro","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.resinv.2024.11.015_bib195","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1165\/rcmb.2019-0144OC","article-title":"Microbiota contribute to obesity-related increases in the pulmonary response to ozone","volume":"61","author":"Tashiro","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.resinv.2024.11.015_bib196","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1159\/000508709","article-title":"The nonantibiotic macrolide EM900 attenuates house dust mite-induced airway inflammation in a mouse model of obesity-associated asthma","volume":"181","author":"Sadamatsu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib197","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.alit.2018.10.004","article-title":"Obesity and severe asthma","volume":"68","author":"Tashiro","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2024.11.015_bib198","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Risankizumab in severe asthma - a phase 2a, placebo-controlled trial","volume":"385","author":"Brightling","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib199","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.201212-2318OC","article-title":"Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma","volume":"188","author":"Busse","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib200","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.89.1.232","article-title":"Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice","volume":"89","author":"Suematsu","year":"1992","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.resinv.2024.11.015_bib201","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","article-title":"Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells","volume":"84","author":"Gauldie","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.resinv.2024.11.015_bib202","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood.V72.6.2070.2070","article-title":"The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6","volume":"72","author":"Shabo","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2024.11.015_bib203","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.it.2014.12.008","article-title":"Versatile functions for IL-6 in metabolism and cancer","volume":"36","author":"Mauer","year":"2015","journal-title":"Trends Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.resinv.2024.11.015_bib204","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1916","article-title":"Interleukin-6: discovery of a pleiotropic cytokine","volume":"8","author":"Kishimoto","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2024.11.015_bib205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","article-title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer","volume":"58","author":"Taga","year":"1989","journal-title":"gp130. Cell."},{"key":"10.1016\/j.resinv.2024.11.015_bib206","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/43219","article-title":"Structure and function of a new STAT-induced STAT inhibitor","volume":"387","author":"Naka","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2024.11.015_bib207","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/43206","article-title":"A family of cytokine-inducible inhibitors of signalling","volume":"387","author":"Starr","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.resinv.2024.11.015_bib208","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib209","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1359-6101(02)00027-8","article-title":"IL-6 in autoimmune disease and chronic inflammatory proliferative disease","volume":"13","author":"Ishihara","year":"2002","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.resinv.2024.11.015_bib210","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11892-005-0071-7","article-title":"The evolving role of inflammation in obesity and the metabolic syndrome","volume":"5","author":"Lee","year":"2005","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.resinv.2024.11.015_bib211","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/ijbs.4874","article-title":"Role of IL-6 in asthma and other inflammatory pulmonary diseases","volume":"8","author":"Rincon","year":"2012","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.resinv.2024.11.015_bib212","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3389\/fimmu.2018.02718","article-title":"Non-redundant functions of IL-6 produced by macrophages and dendritic cells in allergic airway inflammation","volume":"9","author":"Gubernatorova","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib213","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.1900755","article-title":"IL-6 deficiency exacerbates allergic asthma and abrogates the protective effect of allergic inflammation against Streptococcus pneumoniae pathogenesis","volume":"205","author":"Schmit","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.resinv.2024.11.015_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.02.043","article-title":"Treatment of severe persistent asthma with IL-6 receptor blockade","volume":"7","author":"Esty","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2024.11.015_bib215","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1044","article-title":"Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics","volume":"8","author":"Revez","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.resinv.2024.11.015_bib216","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S2213-2600(16)30048-0","article-title":"Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts","volume":"4","author":"Peters","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.11.015_bib217","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/JAA.S276371","article-title":"Biomarkers for overweight in adult-onset asthma","volume":"13","author":"Tashiro","year":"2020","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2024.11.015_bib218","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.alit.2023.08.007","article-title":"Impact of obesity in asthma: possible future therapies","volume":"73","author":"Tashiro","year":"2024","journal-title":"Allergol Int"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:06:24Z","timestamp":1740146784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":218,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2212534524001849"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.11.015","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms and clinical impact of biologic therapies in severe asthma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}